Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donepezil + yokukansankachimpihange is a combination therapy consisting of donepezil, a reversible acetylcholinesterase inhibitor, and yokukansankachimpihange (YKSCH), a traditional Japanese Kampo herbal medicine. Donepezil increases acetylcholine levels in the brain by inhibiting its breakdown, thereby improving cognitive function in Alzheimer's disease. Yokukansankachimpihange is composed of the herbal formula yokukansan with added Citrus unshiu peel and Pinellia tuber; it is used to treat behavioral and psychological symptoms of dementia (BPSD) such as agitation, hallucinations, and irritability. YKSCH acts through modulation of serotonergic (notably 5-HT1A receptor partial agonism) and glutamatergic neurotransmission, as well as possible dopaminergic effects. The combination aims to address both cognitive decline (via donepezil) and neuropsychiatric symptoms (via YKSCH), with studies suggesting reduced need for antipsychotics when both are used together[1][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil + yokukansankachimpihange.